MODERN IDEAS ABOUT THE ETIOLOGY OF UROLITHIASIS
Abstract
Urolithiasis is a systemic recurrent metabolic disease that forms a significant part of the socio–economic burden of the healthcare system. The increase in the prevalence and frequency of recurrence of nephrolithiasis, which has been going on for several decades, highlights the need to find ways for prevention and metaphylaxis of the disease.
The review summarizes current domestic and foreign data on the variable causes of uroliths in the kidneys. The article contains information on innate and modifiable risk factors for urolithiasis: genetic aspects of stone formation, the influence of components metabolic syndrome cluster, the importance of the diet, the role of the intestinal microbiota.
About the Authors
A. N. Rossolovskiy
ФГБОУ ВО «Саратовский государственный медицинский университет им. В.И. Разумовского» Минздрава России
Russian Federation
Russian Federation
D. A. Kondrat'eva
ФГБОУ ВО «Саратовский государственный медицинский университет им. В.И. Разумовского» Минздрава России
Russian Federation
Russian Federation
I. A. Kryuchkov
ФГБОУ ВО «Саратовский государственный медицинский университет им. В.И. Разумовского» Минздрава России
Russian Federation
Russian Federation
M. L. Chekhonatskaya
ФГБОУ ВО «Саратовский государственный медицинский университет им. В.И. Разумовского» Минздрава России
Russian Federation
Russian Federation
References
1. Sorokin I, Mamoulakis C, Miyazawa K, Rodgers A, Talati J, Lotan Y. Epidemiology of stone disease across the world. World J Urol. 2017 Sep;35(9):1301-1320. (in Engl). doi: 10.1007/s00345-017-2008-6.
2. Federal'naya sluzhba gosudarstvennoi statistiki (Rosstat). (The Federal Service for State Statistics (Rosstat)). (In Russ). URL: https://rosstat.gov.ru/folder/13721 (date of application: 04.03.2024). (in Russ)
3. Kaprin A.D., Apolikhin O.I., Sivkov A.V. [et al.] The incidence of urolithiasis in the Russian Federation from 2005 to 2020. Experimental and Clinical Urology, 2022;15(2)10-17. (In Russ). doi: 10.29188/2222-8543-2022-15-2-10-17.
4. Wagner CA. Etiopathogenic factors of urolithiasis. Arch Esp Urol. 2021 Jan;74(1):16-23. (in Engl, Span).
5. Klinicheskie rekomendatsii. Mochekamennaya bolezn': MKB 10: N20: klinicheskie rekomendatsii. Ministerstvo Zdravookhraneniya Rossiiskoi Federatsii, Professional'nye assotsiatsii (Clinical recommendations. Urolithiasis: ICD 10: N20: clinical recommendations) [Elektronnyi resurs]. Rossiiskoe obshchestvo urologov. Rubrikator klinicheskikh rekomendatsii MZ RF. 2020. (In Russ). URL: https://cr.minzdrav.gov.ru/schema/7_1 (date of application: 04.03.2024).
6. Chekhonatskaya M.L., Rossolovsky A.N., Kryuchkov I.A [et al.] Nephroscintigraphy in assessing the functional state of the renal parenchyma in the surgical treatment of coral nephrolithiasis. REJR 2019; 9(3):134-142. (In Russ). doi:10.21569/2222-7415-2019-9-3-134-142.
7. Howles SA, Wiberg A, Goldsworthy M, Bayliss AL, Gluck AK, Ng M, Grout E, Tanikawa C, Kamatani Y, Terao C, Takahashi A, Kubo M, Matsuda K, Thakker RV, Turney BW, Furniss D. Genetic variants of calcium and vitamin D metabolism in kidney stone disease. Nat Commun. 2019 Nov 15;10(1):5175. doi: 10.1038/s41467-019-13145-x. Erratum in: Nat Commun. 2022 May 30;13(1):3115. (in Engl). doi: 10.1038/s41467-019-13145-x.
8. Svetlichnaya D.V., Litvinova M.M. Molecular genetic panel in the assessment of susceptibility to urolithiasis. [in Russian] Materials of the Congress. XIX Congress of the Russian Society of Urology (September 19-21, Rostov-on-Don) 2019:195. (in Engl).
9. Chou YH, Juo SH, Chiu YC, Liu ME, Chen WC, Chang CC, Chang WP, Chang JG, Chang WC. A polymorphism of the ORAI1 gene is associated with the risk and recurrence of calcium nephrolithiasis. J Urol. 2011 May;185(5):1742-6. (in Engl). doi: 10.1016/j.juro.2010.12.094.
10. Apolihin O.I., Sivkov A.V., Konstantinova O.V [et al.] Assotsiatsiya mochekamennoi bolezni u patsientov s razlichnymi sostoyaniyami semeinogo anamneza po urolitiazu s polimorfizmami ego kandidatnykh genov v rossiiskoi populyatsii (Link between urolithiasis in patients with various types of familial history and single nucleotide polymorphisms in Russian population). Eksperimental'naya i klinicheskaya urologiya. 2014; (2): 68-70. (In Russ).
11. Scuteri A, Laurent S, Cucca F, Cockcroft J, Cunha PG, Mañas LR, Mattace Raso FU, Muiesan ML, Ryliškytė L, Rietzschel E, Strait J, Vlachopoulos C, Völzke H, Lakatta EG, Nilsson PM; Metabolic Syndrome and Arteries Research (MARE) Consortium. Metabolic syndrome across Europe: different clusters of risk factors. Eur J Prev Cardiol. 2015 Apr;22(4):486-91. (in Engl). doi: 10.1177/204748731452552.
12. Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW. Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab. 2009 Jun;94(6):1853-78. (in Engl). doi: 10.1210/jc.2008-2291.
13. Klinicheskie rekomendatsii. Rekomendatsii po vedeniyu bol'nykh s metabolicheskim sindromom (Clinical recommendations. Recommendations for the management of patients with metabolic syndrome). Moscow: 2013. (In Russ). URL: https://mzdrav.rk.gov.ru/file/mzdrav_18042014_Klinicheskie_rekomendacii_Metabolicheskij_sindrom.pdf (date of application: 04.03.2024).
14. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009 Oct 20;120(16):1640-5. (in Engl). doi: 10.1161/CIRCULATIONAHA.109.192644
15. Boutari C, Mantzoros CS. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism. 2022 Aug;133:155217. (in Engl). doi: 10.1016/j.metabol.2022.155217.
16. Zdravookhranenie v Rossii (Healthcare in Russia). 2023: Stat. sb./Rosstat. Moscow, 2023:179. (In Russ) URL: https://rosstat.gov.ru/storage/mediabank/Zdravoohran-2023.pdf (date of application: 05.03.2024).
17. Scales CD Jr, Smith AC, Hanley JM, Saigal CS; Urologic Diseases in America Project. Prevalence of kidney stones in the United States. Eur Urol. 2012 Jul;62(1):160-5. (in Engl). doi: 10.1016/j.eururo.2012.03.052.
18. Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA. 2005 Jan 26;293(4):455-62. (in Engl). doi:10.1001/jama.293.4.455.
19. Soligo M, Morlacco A, Zattoni F, Valotto C, DE Giorgi G, Beltrami P. Metabolic syndrome and stone disease. Panminerva Med. 2022 Sep;64(3):344-358. (in Engl). doi: 10.23736/S0031-0808.21.04517-1.
20. Chang CW, Ke HL, Lee JI, Lee YC, Jhan JH, Wang HS, Shen JT, Tsao YH, Huang SP, Geng JH. Metabolic Syndrome Increases the Risk of Kidney Stone Disease: A Cross-Sectional and Longitudinal Cohort Study. J Pers Med. 2021 Nov 6;11(11):1154. (in Engl). doi: 10.3390/jpm11111154.
21. Schwille PO, Schmiedl A, Herrmann U, Wipplinger J. Postprandial hyperinsulinaemia, insulin resistance and inappropriately high phosphaturia are features of younger males with idiopathic calcium urolithiasis: attenuation by ascorbic acid supplementation of a test meal. Urol Res. 1997;25(1):49-58. (in Engl). doi: 10.1007/BF00941906.
22. Shen S, Wei J, Kang W, Wang T. Elucidating shared biomarkers and pathways in kidney stones and diabetes: insights into novel therapeutic targets and the role of resveratrol. J Transl Med. 2023 Jul 21;21(1):491. (in Engl). doi: 10.1186/s12967-023-04356-4.
23. Worcester EM, Gillen DL, Evan AP, Parks JH, Wright K, Trumbore L, Nakagawa Y, Coe FL. Evidence that postprandial reduction of renal calcium reabsorption mediates hypercalciuria of patients with calcium nephrolithiasis. Am J Physiol Renal Physiol. 2007 Jan;292(1):F66-75. (in Engl). doi: 10.1152/ajprenal.00115.2006
24. Krivosíková Z, Spustová V, Dzúrik R. Participation of P-dependent and P-independent glutaminases in rat kidney ammoniagenesis and their modulation by metabolic acidosis, hippurate and insulin. Physiol Res. 1998;47(3):177-83. (in Engl).
25. Chobanian MC, Hammerman MR. Insulin stimulates ammoniagenesis in canine renal proximal tubular segments. Am J Physiol. 1987 Dec;253(6 Pt 2):F1171-7. (in Engl). doi: 10.1152/ajprenal.1987.253.6.F1171.
26. Nagami GT. Luminal secretion of ammonia in the mouse proximal tubule perfused in vitro. J Clin Invest. 1988 Jan;81(1):159-64. (in Engl). doi: 10.1172/JCI113287.
27. Klisic J, Hu MC, Nief V, Reyes L, Fuster D, Moe OW, Ambühl PM. Insulin activates Na(+)/H(+) exchanger 3: biphasic response and glucocorticoid dependence. Am J Physiol Renal Physiol. 2002 Sep;283(3):F532-9. (in Engl). doi: 10.1152/ajprenal.00365.2001.
28. Abate N, Chandalia M, Cabo-Chan AV Jr, Moe OW, Sakhaee K. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int. 2004 Feb;65(2):386-92. (in Engl). doi: 10.1111/j.1523-1755.2004.00386.x.
29. Maalouf NM, Cameron MA, Moe OW, Adams-Huet B, Sakhaee K. Low urine pH: a novel feature of the metabolic syndrome. Clin J Am Soc Nephrol. 2007 Sep;2(5):883-8. (in Engl). doi: 10.2215/CJN.00670207.
30. Bobulescu IA, Park SK, Xu LHR, Blanco F, Poindexter J, Adams-Huet B, Davidson TL, Sakhaee K, Maalouf NM, Moe OW. Net Acid Excretion and Urinary Organic Anions in Idiopathic Uric Acid Nephrolithiasis. Clin J Am Soc Nephrol. 2019 Mar 7;14(3):411-420. (in Engl). doi: 10.2215/CJN.10420818.
31. Trinchieri A, Maletta A, Lizzano R, Marchesotti F. Potential renal acid load and the risk of renal stone formation in a case-control study. Eur J Clin Nutr. 2013 Oct;67(10):1077-80. (in Engl). doi: 10.1038/ejcn.2013.155.
32. Ferraro PM, Mandel EI, Curhan GC, Gambaro G, Taylor EN. Dietary Protein and Potassium, Diet-Dependent Net Acid Load, and Risk of Incident Kidney Stones. Clin J Am Soc Nephrol. 2016 Oct 7;11(10):1834-184. (in Engl). doi: 10.2215/CJN.01520216.
33. Lin PH, Ginty F, Appel LJ, Aickin M, Bohannon A, Garnero P, Barclay D, Svetkey LP. The DASH diet and sodium reduction improve markers of bone turnover and calcium metabolism in adults. J Nutr. 2003 Oct;133(10):3130-6. (in Engl). doi: 10.1093/jn/133.10.3130
34. Anand S, Mande SS. Host-microbiome interactions: Gut-Liver axis and its connection with other organs. NPJ Biofilms Microbiomes. 2022 Nov 1;8(1):89. (in Engl). doi: 10.1038/s41522-022-00352-6.
35. Siener R, Bangen U, Sidhu H, Hönow R, von Unruh G, Hesse A. The role of Oxalobacter formigenes colonization in calcium oxalate stone disease. Kidney Int. 2013 Jun;83(6):1144-9. (in Engl). doi: 10.1038/ki.2013.104.
36. Zhang R, Zhao W, Zhao R, Zhao Y, Zhang Y, Liang X. Causal relationship in gut microbiota and upper urinary urolithiasis using Mendelian randomization. Front Microbiol. 2023 May 18;14:1170793. (in Engl). doi: 10.3389/fmicb.2023.1170793.
37. Pan Y, Su J, Liu S, Li Y, Xu G. Causal effects of gut microbiota on the risk of urinary tract stones: A bidirectional two-sample mendelian randomization study. Heliyon. 2024 Feb 14;10(4):e25704. (in Engl). doi: 10.1016/j.heliyon.2024.e25704.
Review
For citations:
Rossolovskiy A.N., Kondrat'eva D.A., Kryuchkov I.A., Chekhonatskaya M.L. MODERN IDEAS ABOUT THE ETIOLOGY OF UROLITHIASIS. Bashkortostan Medical Journal. 2024;19(3):85-92. (In Russ.)
Views:
32
Email this article 
